JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 166 filers reported holding JUNO THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.25 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2016 | $98,000 | +415.8% | 3,250 | +550.0% | 0.03% | +400.0% |
Q2 2016 | $19,000 | -50.0% | 500 | -50.0% | 0.01% | -62.5% |
Q1 2016 | $38,000 | -39.7% | 1,000 | -29.8% | 0.02% | -33.3% |
Q4 2015 | $63,000 | +152.0% | 1,425 | +128.0% | 0.02% | +200.0% |
Q3 2015 | $25,000 | – | 625 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
SIB LLC | 100,000 | $3,001,000 | 2.42% |
Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
First Washington CORP | 65,320 | $1,960,000 | 1.10% |
PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |